AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States
AbbVie News Center • • general
Key Points:
- AbbVie is investing $380 million to build two advanced pharmaceutical ingredient (API) manufacturing facilities at its North Chicago campus, integrating AI technologies to support next-generation neuroscience and obesity medicines.
- Construction will start in spring 2026, with the facilities expected to be fully operational by 2029, creating approximately 300 new jobs including engineers, scientists, and manufacturing operators.
- This investment is part of AbbVie's broader $100 billion commitment over the next decade to U.S. research, development, and capital investments, enhancing its domestic manufacturing capabilities.
- AbbVie has also announced expansions and acquisitions in other U.S. states, including a device manufacturing facility in Arizona and investments in Massachusetts, with additional manufacturing investments anticipated in 202
